Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$20.91 0.32 (1.51%) as of 4:30 Fri 5/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.49(B)
Last Volume: 1,548,181 Avg Vol: 2,440,013
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 14.9
Insider 6 Months    : 16.6
Insider 3/6 Months : 32
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 190,000 310,409 310,409 310,409
Total Buy Value $3,932,734 $6,534,772 $6,534,772 $6,534,772
Total People Bought 1 1 1 1
Total Buy Transactions 1 2 2 2
Total Shares Sold 77,148 336,706 542,969 981,371
Total Sell Value $1,703,116 $7,468,007 $11,664,525 $19,365,156
Total People Sold 3 5 6 10
Total Sell Transactions 3 9 13 25
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 985
  Page 12 of 40  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Morrissey Michael M President and CEO   •       •      –    2021-02-24 4 GD $0.00 $0 D/D 67,374 491,813     -
   Cohen Charles Director   –       •      –    2021-02-24 4 S $22.69 $907,600 D/D (40,000) 181,375 19%     
   Cohen Charles Director   –       •      –    2021-02-24 4 OE $3.38 $135,200 D/D 40,000 221,375     -
   Willsey Lance Director   –       •      –    2021-02-23 4 S $21.92 $877,136 D/D (40,000) 424,415 18%     
   Willsey Lance Director   –       •      –    2021-02-23 4 OE $3.38 $135,200 D/D 40,000 464,415     -
   Poste George Director   –       •      –    2021-02-22 4 OE $3.38 $135,200 D/D 40,000 197,992     -
   Marchesi Vincent T Director   –       •      –    2021-02-22 4 S $22.29 $537,122 D/D (24,097) 66,115 15%     
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-18 4 S $22.35 $1,117,500 D/D (50,000) 540,597 19%     
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-18 4 OE $1.70 $85,000 D/D 50,000 590,597     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-17 4 S $22.50 $1,125,000 D/D (50,000) 540,597 21%     
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-17 4 OE $1.70 $85,000 D/D 50,000 590,597     -
   Willsey Lance Director   –       •      –    2021-02-16 4 S $21.90 $1,095,000 D/D (50,000) 424,415 -7%     
   Feldbaum Carl B Director   –       •      –    2021-02-16 4 S $21.96 $439,200 D/D (20,000) 8,521 -7%     
   Feldbaum Carl B Director   –       •      –    2021-02-16 4 OE $3.38 $67,600 D/D 20,000 28,521     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-02-15 4 D $21.91 $81,461 D/D (3,718) 340,072     -
   Morrissey Michael M President and CEO   •       •      –    2021-02-15 4 D $21.91 $214,477 D/D (9,789) 559,187     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-02-15 4 D $21.91 $30,674 D/D (1,400) 245,487     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-02-15 4 D $21.91 $62,619 D/D (2,858) 540,597     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-02-15 4 D $21.91 $36,918 D/D (1,685) 589,113     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-02-15 4 D $21.91 $89,941 D/D (4,105) 292,441     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-02-12 4 S $21.57 $970,650 D/D (45,000) 246,887 -4%     
   Morrissey Michael M President and CEO   •       •      –    2021-02-03 4 D $22.56 $1,470,686 D/D (65,190) 568,976     -
   Morrissey Michael M President and CEO   •       •      –    2021-02-03 4 A $0.00 $0 D/D 23,238 409,879     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-02-03 4 D $22.56 $254,184 D/D (11,267) 291,887     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-02-03 4 A $0.00 $0 D/D 63,909 303,154     -
  985 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 12 of 40
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us